Research programme: selective cytokine inhibitory drugs - Celgene
Alternative Names: CC-5048Latest Information Update: 04 Dec 2019
At a glance
- Originator Celgene Corporation
- Class Small molecules
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Inflammation; Respiratory tract disorders
Most Recent Events
- 20 Nov 2019 Celgene Corporation has been acquired by Bristol Myers Squibb
- 15 Apr 2008 Discontinued - Preclinical for Cancer in USA (PO)
- 15 Apr 2008 Discontinued - Preclinical for Inflammation in USA (PO)